Alx Oncology Holdings INC 8-K filings

ALX Oncology announced second quarter 2026 financial results, reporting a reduced net loss and providing updates on its evorpacept and ALX2004 clinical programs, alongside leadership appointments and debt refinancing.

ALX Oncology Holdings Inc. has appointed Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel, with Corey Goodman, Ph.D. stepping down as Chairman.

ALX Oncology Holdings Inc. has entered into a new $50 million secured term loan agreement to refinance existing debt and support general corporate operations.

ALX Oncology Holdings Inc. reported voting results from its Annual Meeting held on June 10, 2026, with key proposals including director elections and executive compensation.

ALX Oncology reported Q1 2026 financial results, highlighting encouraging clinical data for evorpacept in HER2-positive breast cancer and strengthening its leadership team.

ALX Oncology Holdings Inc. announced the appointment of Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026, bringing extensive experience in biopharmaceutical development and operations.

ALX Oncology announced positive full year 2025 financial results, validated its evorpacept biomarker strategy, and extended its cash runway through the first half of 2028 following a $150 million equity offering.

ALX Oncology Holdings Inc. announced the pricing of an underwritten offering of common stock and pre-funded warrants, expecting to raise approximately $150 million to fund clinical development.

ALX Oncology announced new clinical data showing CD47 expression predicts evorpacept activity in HER2-positive metastatic breast cancer, alongside preliminary cash estimates.

ALX Oncology Holdings Inc. amended its 2025 Inducement Equity Incentive Plan to increase the aggregate number of shares reserved for issuance to 2.8 million, aiming to attract and retain key talent.

ALX Oncology announced its third-quarter 2025 financial results and provided a corporate update, highlighting positive ASPEN-06 data and progress in its ALX2004 and ASPEN-09 trials.

ALX Oncology announced key leadership changes with Dr. Barbara Klencke appointed Interim Chief Medical Officer and Dr. Alan Sandler returning to the Board, alongside regaining Nasdaq minimum bid price compliance.

ALX Oncology Holdings Inc. announced its second quarter 2025 financial results, highlighted by an extended cash runway into Q1 2027 and positive biomarker data for its lead oncology programs.

ALX Oncology Holdings Inc. announced the successful election of two Class II directors, advisory approval of executive compensation, and ratification of KPMG LLP as its independent auditor at its Annual Meeting held on June 11, 2025.

ALX Oncology announced its Q1 2025 financial results, a corporate update, and a prioritized development strategy for evorpacept in combination with anti-cancer antibodies.

ALX Oncology Holdings Inc. received a notice from Nasdaq on April 23, 2025, indicating non-compliance with the minimum bid price requirement for continued listing.

ALX Oncology announced its fourth quarter and full year 2024 financial results, highlighting clinical trial progress, strategic prioritization, and key leadership additions, with a cash runway extended into Q4 2026.

ALX Oncology is reducing its workforce by approximately 30% and eliminating the President and Chief Scientific Officer position as part of a pipeline prioritization and cash preservation strategy.

ALX Oncology appoints Harish Shantharam as Chief Financial Officer and adds Barbara Klencke and Chris Takimoto to its Board of Directors.

ALX Oncology Holdings Inc. has adopted a new equity incentive plan to attract new employees, reserving 1,500,000 shares for issuance.

ALX Oncology appoints Alan Sandler as Chief Medical Officer, effective November 10, 2024, while also announcing the departure of Chief Financial Officer Peter Garcia.

ALX Oncology announced positive topline data from its ASPEN-06 Phase 2 trial, along with its third quarter 2024 financial results, and the resignation of its CFO.

ALX Oncology's Chief Medical Officer, Sophia Randolph, M.D., Ph.D., has resigned effective October 11, 2024, with a transition plan including a separation agreement and consulting services.

ALX Oncology announced positive results from its ASPEN-06 Phase 2 trial for evorpacept in gastric cancer and provided a corporate update for the second quarter of 2024.

ALX Oncology has appointed Alan Sandler, M.D., to its Board of Directors while Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., step down from the board to focus on their senior leadership roles within the company.

ALX Oncology Holdings Inc. held its annual meeting on June 12, 2024, where stockholders elected three Class I directors, approved executive compensation, and ratified the appointment of KPMG LLP as the independent auditor.

ALX Oncology announced positive clinical trial results for evorpacept and its first quarter 2024 financial results, highlighting progress in its oncology pipeline.

ALX Oncology reports the immediate resignations of two board members due to health reasons and a new professional position, leading to board reclassifications and committee changes.

ALX Oncology announced positive results from a Phase 2 trial of evorpacept in gastric cancer, along with a successful public offering and financial results for 2023.